Drug intelligence / Profile preview

NT-310

Development stage: Preclinical
Lead developer: Merrimack Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

NT-310 is a non-targeted nanoliposomal formulation of the taxane docetaxel. Developed by Merrimack Pharmaceuticals, it served as the non-targeted control or comparator for MM-310, an EphA2-targeted docetaxel nanoliposome. While MM-310 utilizes an scFv targeting arm to bind to EphA2-overexpressing tumor cells, NT-310 relies primarily on the enhanced permeability and retention (EPR) effect for intratumoral accumulation. Preclinical studies in gastric, esophageal, and triple-negative breast cancer models have utilized NT-310 to evaluate the relative contribution of active cellular targeting to the overall efficacy and microdistribution of liposomal docetaxel delivery.

Other names: non-targeted docetaxel nanoliposome

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on NT-310.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT-310.

Explore the full profile